Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kristi Dively

Addiction Medicine Lancaster, PA Doctor of Osteopathy

NPI 1063447852 CMS profile 963002

555 N Duke St, Lancaster, PA 17602

Open in the dashboard

General payments

$1,313

58 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristi Dively of Lancaster, PA is reported in the CMS Open Payments database as having received $1,313 across 58 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Addiction Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $43 2
2024 General $247 9
2023 General $206 11
2022 General $305 16
2021 General $216 12
2019 General $295 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristi Dively
  • Addiction Medicine median
  • Middle half of Addiction Medicine
  • National median

In program year 2025, general payments to Kristi Dively were reported at $43. Among 306 Addiction Medicine profiles paid that year, the median was $147 and the middle half received between $46 and $381.

Show as a table
Year Kristi Dively Addiction Medicine median Middle half National median
2019 $295 $96 $32–$265 $163
2020 $0 $53 $20–$176 $114
2021 $216 $86 $24–$265 $132
2022 $305 $89 $27–$330 $149
2023 $206 $102 $39–$363 $160
2024 $247 $110 $38–$311 $164
2025 $43 $147 $46–$381 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $480 26 payments
  2. Alkermes, Inc. $261 9 payments
  3. Indivior Inc. $237 9 payments
  4. Braeburn Inc. $168 5 payments
  5. Hikma Pharmaceuticals USA $67 4 payments
  6. Otsuka America Pharmaceutical, Inc. $37 2 payments
  7. Orexo US, Inc. $30 1 payment
  8. GlaxoSmithKline, LLC. $18 1 payment
  9. kaleo, Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,300 57 payments
  2. Education $13 1 payment
Products named General payments · program years 2019–2025
  1. MAVYRET $288 14 payments
  2. VRAYLAR $192 12 payments
  3. BRIXADI $168 5 payments
  4. ARISTADA Cns $159 3 payments
  5. ARISTADA Cns $159 3 payments
  6. ARISTADA INITIO $159 3 payments
  7. SUBLOCADE Oud $153 7 payments
  8. ARISTADA Cns $140 2 payments
  9. ARISTADA Cns $140 2 payments
  10. SUBLOCADE Oud $83 2 payments
  11. Other $436 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

18

Median for Obstetrics & Gynecology: 65

Drug cost

$1,474

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

100%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 18 $1,474

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BRIXADI
  • Braeburn Inc. $134
$134 — —
VRAYLAR
  • AbbVie, Inc. $54
$54 — —
MAVYRET
  • AbbVie, Inc. $26
$26 — —
SUBLOCADE
  • Indivior Inc. $20
$20 — —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

58 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Addiction Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record